Advanced Insights into the Prevention, Treatment and Management of Alzheimer's Disease

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
Avanir Pharmaceuticals and Biogen

Alzheimer’s disease is the most common form of dementia, a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Over time the disease destroys large areas of the brain, resulting in cellular loss and dysfunction, a gradual loss of memory, problems with reasoning or judgment, disorientation, difficulty in learning, loss of language skills, and decline in the ability to perform routine tasks. Today, there is no treatment that can reverse the disease, and all the available treatments to Alzheimer’s are symptomatic therapies. The standard medical treatments include cholinesterase inhibitors, a partial N-methyl-D-aspartate (NMDA) antagonist and memantine, which helps with brain cell communication. With that being said, treatment for Alzheimer's disease is entering into a promising stage, with several new drugs beginning clinical trials. Many of these new therapies are based on an understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease. Currently, an autopsy or brain biopsy is the only way to make a definitive diagnosis of Alzheimer’s disease. In clinical practice, the diagnosis is typically made on the basis of the history and findings on Mental Status Examination in addition to neurological exam, blood testing and brain imaging. There is no single test that can show whether a person has Alzheimer's.

PCPs are increasingly called on to provide care for cognitively impaired individuals, playing critical roles in detecting early symptoms of dementia, communicating with patients and caregivers about the disease, coordinating with specialists on multimodal therapeutic plans, and following up to tailor treatment, minimize complications, and head off medical crises.

Upon Completion of this activity, participants will be able to:

  • Discuss the current status of Alzheimer’s disease

  • Identify the diagnosis and placement of therapeutic options used for the treatment of agitation in patients with Alzheimer’s disease

  • Explore the role of biomarkers, tools, and imaging for current use in the diagnosis of Alzheimer’s disease

  • Analyze emerging therapeutic options that can achieve new treatment targets in patients who do not respond to traditional therapies

Faculty: Naushira Pandya MD, CMD, FACP
Professor and Chair, Department of Geriatrics
Project Director, Geriatric Education Center
Nova Southeastern University College of Osteopathic Medicine


Dr. Pandya has no financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.  Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
Avanir Pharmaceuticals and Biogen

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue